Immunome, Inc. granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 344,000 shares of common stock to 17 new employees on July 1, 2026. The Compensation Committee of the Company’s Board of Directors approved the grants as an employment inducement under Nasdaq Listing Rule 5635(c)(4). The awards were issued pursuant to the Company’s 2024 Inducement Plan.

Each stock option carries an exercise price of $21.49 per share, equal to the Company’s closing sales price on the grant date. The options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date. The remaining 75% will vest monthly over the subsequent 36 months, contingent on the employee's continued service relationship with Immunome through the applicable vesting dates.

The stock options are subject to the terms and conditions of the 2024 Inducement Plan and the individual stock option agreements covering each grant. Immunome is a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies.

Key Details of the Grant

The Company’s pipeline includes varegacestat, an investigational gamma secretase inhibitor for which a New Drug Application (NDA) has been submitted to the U.S. FDA. Other assets include IM-1021, a clinical-stage ROR1 antibody-drug conjugate (ADC); IM-1617, a clinical-stage solid tumor ADC; and IM-3050, an IND-cleared FAP-targeted radiotherapy.

Wedbush analyst David Nierengarten has reiterated an Outperform rating on Immunome (NASDAQ: IMNM), maintaining a price target of $31. This endorsement reflects continued confidence in the company's performance and market position.

The rating and price target remain unchanged, signaling a steady outlook for the stock. Investors following Immunome will note the consistency in Wedbush's assessment.